JACE for Giant Congenital Melanocytic Nevus Covered by Health Insurance: J-TEC

Japan Tissue Engineering (J-TEC) announced on December 1 that its cultured epithelial autograft product JACE, a regenerative medicine product, became eligible for reimbursement under health insurance programs on December 1 for the treatment of giant congenital melanocytic nevus (GCMN). JACE...read more